je.st
news
Tag: world
Construction Science Fiction: New World
2013-10-30 10:45:37| ENR.com: Headline News
What happened to the colonists constructing an outpost in the hostile environment of a planet light years away? A rescue mission tries to unravel the mystery.
Tags: world
science
construction
fiction
Point and Poll: Germany is Leading Europe and the World to a Sustainable Energy Future
2013-10-30 04:00:00| Transmission & Distribution World
At the end of 2012, Germany had 25 GW of solar PV installed and is shooting to reach a total of 52 gigawatts by 2020. read more
Prince Charles: Syria Conflict Is Partly Down To Global Warming, World Economic
2013-10-30 02:54:00| Climate Ark Climate Change & Global Warming Newsfeed
Huffington Post: The environment is a "significant" factor in the Syrian conflict that has killed more than 100,000 people, Prince Charles has claimed. The heir to the throne said a drought and the the depletion of natural resources was one of the key reasons for the bitter fighting. In a keynote speech to Islamic business leaders, Charles said this had been "inexplicably" not reported by the media. "The tragic conflict in Syria provides a terrifyingly graphic example, where a severe drought for the last...
Tags: world
global
economic
charles
Duke Energy Apprentice Wins Best in the World at International Lineman's Rodeo
2013-10-29 21:05:00| Transmission & Distribution World
Duke Energy apprentice Joe Hyrkas proved he is best in the world at the International Lineman's Rodeo Oct. 19 in Bonner Springs, Kansas, U.S. read more
Tags: world
international
energy
wins
Merck Announces Presentation of Interim Data from Phase 1B Study of MK-3475, Investigational anti-PD-1 Immunotherapy, in Previously-Treated Patients with Non-Small Cell Lung Cancer (NSCLC) at 15th World Conference on Lung Cancer
2013-10-29 06:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Phase II/III Trial of MK-3475 in Patients with NSCLC Currently Enrolling WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from a Phase 1B trial (PN001) evaluating MK-3475, an investigational anti-PD-1 immunotherapy, in patients with previously-treated non-small cell lung cancer (NSCLC). The data were presented today by Dr. Language: English Contact: MerckMedia Contacts:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-500-1101orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [813] [814] [815] [816] [817] [818] [819] [820] [821] [822] [823] [824] [825] [826] [827] [828] [829] [830] [831] [832] next »